Geron (GERN) Other Non-Current Liabilities (2012 - 2026)
Geron (GERN) posted Other Non-Current Liabilities of $110.4 million for Q1 2026, down 1.56% sequentially from $112.1 million in Q4 2025, and little changed YoY from $110.4 million in Q1 2025.
Geron (GERN) Other Non-Current Liabilities (2012 - 2026) Analysis & Trends
Geron has reported Other Non-Current Liabilities for 6 years, with the latest figure at $110.4 million in Q1 2026.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $110.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $110.4 million (changed 0.0% YoY) and the FY2025 annual result came in at $112.1 million, up 7.39% from the prior year.
- Other Non-Current Liabilities slipped to $110.4 million in Q1 2026 per GERN's latest filing, from $112.1 million in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $112.1 million in Q4 2025 and troughed at $104.4 million in Q4 2024.
- A 3-year average of $109.6 million and a median of $110.4 million in 2025 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities climbed 7.39% in 2025, then increased 0.0% in 2026.
- Over 3 years, Other Non-Current Liabilities stood at $104.4 million in 2024, then rose by 7.39% to $112.1 million in 2025, then slipped by 1.56% to $110.4 million in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $110.4 million, $112.1 million, and $110.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Geron | 1.02 Mn | -299.83 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 108.93 Mn |
| Mar 31, 2026 | 110.38 Mn |
| Dec 31, 2025 | 112.13 Mn |
| Sep 30, 2025 | 110.04 Mn |
| Jun 30, 2025 | 110.53 Mn |
| Mar 31, 2025 | 110.38 Mn |
| Dec 31, 2024 | 104.42 Mn |
| Dec 31, 2014 | 16,000.00 |
| Sep 30, 2014 | 1,000.00 |
| Jun 30, 2014 | 290,000.00 |
| Mar 31, 2014 | 143,000.00 |
| Dec 31, 2013 | 367,000.00 |
| Sep 30, 2013 | 258,000.00 |
| Jun 30, 2013 | 50,000.00 |
| Mar 31, 2013 | 26,000.00 |
| Dec 31, 2012 | 51,000.00 |